News
In experiments in mouse tissues and human cells, researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged ...
TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a ...
In celebration of Ophthalmology Times ' 50th anniversary, we asked leading experts in the field, in a perfect world, if they ...
Hosted on MSN9mon
NRXBF Announces Important Test Results
NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...
The first ever trial of microsurgical suture repair vs. nerve alignment for digital nerve injuries suggests suture repair ...
Hosted on MSN3mon
NRXBF Makes Significant Announcement
NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...
Each year thousands of patients face life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed. New research in mice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback